{"url_path":"/sec/vstm/8-k/2026-06-17/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1526119/0001104659-26-074915-index.html","accession_number":"0001104659-26-074915","cik":"0001526119","ticker":"VSTM","issuer_name":"Verastem, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1526119/0001104659-26-074915-index.html","primary_entity_key":"0001526119","primary_entity_name":"Verastem, Inc."},"word_count":297,"has_tables":true,"body_markdown":"**Item 8.01 Other Events**\n\n** **\n\n**Positive Updated Results from RAMP 205 Evaluating Avutometinib\nPlus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer**\n\n** **\n\nOn June 17, 2026, the Company announced positive updated safety and\nefficacy results from the RAMP 205 Phase 1b/2a trial Recommended Phase 2 Dose (“RP2D”) cohort of 29 patients evaluating avutometinib\nplus defactinib in combination with gemcitabine and nab-paclitaxel in first-line mPDAC.\n\n \n\nIn the Phase 1b/2a trial, 29 patients were enrolled and treated at\nthe RP2D with avutometinib 2.4 mg twice weekly, defactinib 200 mg twice daily for 3 weeks on and one week off, and gemcitabine (800 mg/m2)\nplus nab-paclitaxel (125 mg/m2) administered on Days 1, 8, and 15 of each 28-day cycle. At diagnosis, 90% of patients presented with metastatic\ndisease. As of the June 5, 2026 data cutoff, with a median follow up of 9.8 months, the combination demonstrated clinical activity, including an 86% overall survival rate at 6 months. The progression-free survival rate at six months was 68%, and the confirmed objective\nresponse rate was 52%. At the RP2D dose level, the majority (83%) of patients experienced tumor shrinkage. Nine patients remain\non treatment at this dose level. Adverse events remained generally consistent with the previously reported safety and tolerability profile,\nwith no new safety signals observed.\n\n \n\n**Dosing of First Patient in TARGET-D 201 Phase 2 Registration-Directed\nTrial of VS-7375**\n\n** **\n\nOn June 16, 2026, the Company also announced\nthat the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral\nKRAS G12D (ON/OFF) inhibitor, to treat patients with KRAS G12D-mutated mPDAC.\n\n \n\nTARGET-D 201 is a Phase 2, open-label, multi-center study to evaluate\nVS-7375 at 900 mg daily both as monotherapy and in combination with full-dose cetuximab in patients with second-line mPDAC."}